The startup has developed a patented breath diagnostics platform that employs cheminformatics and machine learning to detect pneumonia earlier than traditional methods. This non-invasive tool integrates with hospital EMR systems, providing actionable insights for optimal antibiotic treatment selection.
Funding
$7.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for diagnosing pneumonia can be invasive and time-consuming, leading to delayed treatment and potentially adverse patient outcomes. Late diagnosis of pneumonia contributes to significant healthcare losses due to increased treatment costs and prolonged hospital stays.
Solution
RespirationScan offers a non-invasive breath diagnostics platform, ExhalePN™, that utilizes cheminformatics and machine learning to detect pneumonia earlier than traditional methods. By analyzing volatile organic compounds (VOCs) in a patient's breath, the platform provides timely and precise insights for optimal antibiotic treatment selection. The platform aims to decrease the time to diagnosis and treatment, improve clinical outcomes, and reduce costs to healthcare systems. ExhalePN seamlessly integrates into existing hospital EMR systems, creating more efficient clinical support systems.
Target Audience
The primary target audience includes healthcare systems, hospitals, and clinicians seeking to improve pneumonia diagnosis and treatment outcomes.
Features
- Patented breath diagnostics platform employing cheminformatics and machine learning algorithms
- Non-invasive diagnostic method based on the analysis of volatile organic compounds (VOCs) in human breath
- Early detection of pneumonia, up to 48 hours sooner than current methods
- Actionable insights for doctors to determine the best antibiotic treatment for patients
- Seamless integration into hospitals' existing EMR systems
- Continuous learning software that diagnoses new disease states by analyzing VOCs